NasdaqGS - Delayed Quote • USD
Karyopharm Therapeutics Inc. (KPTI)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 7:23 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 7 | 7 | 7 | 7 |
Avg. Estimate | -0.33 | -0.31 | -1.23 | -1.01 |
Low Estimate | -0.37 | -0.34 | -1.33 | -1.27 |
High Estimate | -0.28 | -0.27 | -1.09 | -0.77 |
Year Ago EPS | -0.3 | -0.29 | -1.25 | -1.23 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 6 | 6 | 6 | 6 |
Avg. Estimate | 34.47M | 36.42M | 146.52M | 164.74M |
Low Estimate | 31.7M | 34.6M | 142.44M | 130.2M |
High Estimate | 38.36M | 39.4M | 150.84M | 209.72M |
Year Ago Sales | 36.6M | 37.58M | 146.03M | 146.52M |
Sales Growth (year/est) | -5.80% | -3.10% | 0.30% | 12.40% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.37 | -0.34 | -0.28 | -0.31 |
EPS Actual | -0.3 | -0.29 | -0.3 | -0.36 |
Difference | 0.07 | 0.05 | -0.02 | -0.05 |
Surprise % | 18.90% | 14.70% | -7.10% | -16.10% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.33 | -0.31 | -1.23 | -1.01 |
7 Days Ago | -0.33 | -0.31 | -1.23 | -1.01 |
30 Days Ago | -0.33 | -0.31 | -1.23 | -1.01 |
60 Days Ago | -0.3 | -0.3 | -1.1 | -1.01 |
90 Days Ago | -0.3 | -0.29 | -1.09 | -0.96 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | KPTI | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -10.00% | -- | -- | 2.60% |
Next Qtr. | -6.90% | -- | -- | 13.40% |
Current Year | 1.60% | -- | -- | 5.20% |
Next Year | 17.90% | -- | -- | 13.30% |
Next 5 Years (per annum) | -30.30% | -- | -- | 11.11% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | HC Wainwright & Co.: Buy to Buy | 3/1/2024 |
Maintains | Piper Sandler: Overweight to Overweight | 11/3/2023 |
Maintains | RBC Capital: Outperform to Outperform | 11/3/2023 |
Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 8/7/2023 |
Maintains | Piper Sandler: Overweight to Overweight | 8/3/2023 |
Maintains | RBC Capital: Outperform to Outperform | 8/3/2023 |
Related Tickers
FGEN FibroGen, Inc.
1.0200
+3.63%
TGTX TG Therapeutics, Inc.
13.91
-0.50%
OCUL Ocular Therapeutix, Inc.
4.2000
-9.58%
HRTX Heron Therapeutics, Inc.
2.5500
-3.77%
ADCT ADC Therapeutics SA
4.4400
-7.11%
TSVT 2seventy bio, Inc.
4.2900
+0.47%
ADAP Adaptimmune Therapeutics plc
1.0600
-1.85%
MCRB Seres Therapeutics, Inc.
0.7427
+1.81%
ACET Adicet Bio, Inc.
1.8100
-3.47%
CARA Cara Therapeutics, Inc.
0.7000
+4.23%